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Abstract
Background: The secreted enzyme EndoS, an endoglycosidase from Streptococcus pyogenes, hydrolyzes the N-
linked glycan of the constant region of immunoglobulin G (IgG) heavy chain and renders the antibody unable to
interact with Fc receptors and elicit effector functions. In this study we couple targeted allelic replacement
mutagenesis and heterologous expression to elucidate the contribution of EndoS to group A Streptococcus (GAS)
phagocyte resistance and pathogenicity in vitro and in vivo.
Results: Knocking out the EndoS gene in GAS M1T1 background revealed no significant differences in bacterial
survival in immune cell killing assays or in a systemic mouse model of infection. However, exogenous addition and
heterologous expression of EndoS was found to increase GAS resistance to killing by neutrophils and monocytes in
vitro. Additionally, heterologous expression of EndoS in M49 GAS increased mouse virulence in vivo.
Conclusions: We conclude that in a highly virulent M1T1 background, EndoS has no significant impact on GAS
phagocyte resistance and pathogenicity. However, local accumulation or high levels of expression of EndoS in
certain GAS strains may contribute to virulence.
Background
Group A Streptococcus (GAS, S. pyogenes) is a human-
specific pathogen producing diseases ranging from phar-
yngitis and impetigo to severe, invasive conditions such
as necrotizing fasciitis and streptococcal toxic shock
syndrome [1]. Causing an estimated 500,000 deaths
annually [2], GAS is one of the world’s most important
pathogens, reflecting its wide repertoire of virulence fac-
tors that interfere with host immune clearance mechan-
isms [3]. A hypothesized GAS immune evasion factor is
the secreted enzyme EndoS, an endoglycosidase posses-
sing a highly specific hydrolyzing activity toward the N-
linked glycan of immunoglobulin G (IgG) [4]. The IgG
heavy chain is N-glycosylated at asparagine 297 with a
complex biantennary oligosaccharide that is crucial for
the interaction with Fc gamma receptors (FcgRs) on
phagocytic cells [5-7]. Experimentally, enzymatic degly-
cosylation of murine IgG can decrease complement
activation, binding of IgG to FcgRs on macrophages, and
antibody-mediated cytotoxicity [5].
EndoS is specific to native IgG, which is in contrast to
many related endoglycosidases that requires denatura-
tion of their glycoprotein substrates [8,9]. Furthermore,
pretreatment of IgG with recombinant EndoS
diminishes its ability to opsonize bacteria and interact
with FcgRs on leukocytes [10,11]. The activity of EndoS
on IgG heavy chain glycans is well characterized and
conserved among GAS serotypes [12]. However, a
potential role of endogenous EndoS expression by the
GAS bacterium in phagocyte resistance and virulence
has not been elucidated. We hypothesize that EndoS
contributes to GAS virulence by hydrolyzing the N-
linked glycan on IgG and thereby impairing antibody
mediated functions in the immune system. Here we
couple targeted allelic replacement mutagenesis and het-
erologous gene expression to study EndoS activity dur-
ing bacterial-host cell interaction in vitro and in vivo.
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Results
Generation of EndoS mutants and heterologous
expression
To investigate the contribution of EndoS to GAS and
host-cell interactions an allelic replacement knockout in
the M1T1 background was constructed and denoted 5448
ΔndoS. Heterologous expression of EndoS in a non-native
EndoS producing GAS strain, NZ131 (serotype M49), was
established by transformation of the EndoS expressing
plasmid pNdoS. Loss- and gain-of-function was confirmed
by Western immunoblot (Figure 1A) and IgG glycan
hydrolysis assays (Figure 1B) [8]. As suspected no detect-
able EndoS was identified in the supernatants of the
5448ΔndoS strain, and heterologous expression of EndoS
in NZ131 was successful. In addition, higher levels of
EndoS were observed in the overexpressing strain NZ131
[pNdoS] compared to the wild-type M1 strain 5448.
Neutrophil killing assay
The phagocytic resistance of GAS with and without
EndoS contribution was investigated in a human neutro-
phil killing assay with GAS strains 5448ΔndoS and wild-
type 5448. Loss-of-function did not reveal significant
difference in GAS resistance to phagocyte killing in the
M1T1 background (Figure 1C). In the same M1T1 back-
ground, exogenous recombinant EndoS, rEndoS, or PBS
was used to pretreat plasma to investigate phagocytic
resistance contribution of the enzyme itself. It was
found that rEndoS increases GAS survival in the pre-
sence of neutrophils and plasma containing GAS antibo-
dies (Figure 1D). The contribution of EndoS to GAS
virulence was also studied in the less virulent strain
NZ131 (serotype M49) in gain-of-function analysis. The
results reveal that heterologous overexpression of EndoS
in M49, NZ131[pNdoS] increased GAS resistance to
killing by human neutrophils (Figure 1E).
Monocyte killing assay
As with neutrophil killing assays, no significant differ-
ence in bacterial survival was detected in the monocytic
killing assays when comparing M1T1 GAS strain 5448
to the isogenic ndoS knockout strain (Figure 2A). Pre-
treatment of plasma with exogenous rEndoS resulted in
a significant increase in GAS resistance to killing by
monocytes (Figure 2B), as did heterologous expression
of EndoS in the less virulent strain NZ131 (Figure 2C).
C
D












































Figure 1 EndoS expression and activity, and neutrophil killing assays. (A) Western immunoblot showing EndoS expression in bacterial
supernatants. SpeB is shown as a loading control. (B) Lectin blot analysis of murine IgG incubated with bacterial supernatants or rEndoS as a
positive control. Opsonized bacterial survival in the presence of human neutrophils: (C) M1T1 GAS strain 5448 and isogenic ndoS knockout,
5448ΔndoS. (D) Exogenous treatment of plasma with rEndoS prior to opsonization of GAS. (E) Heterologous expression of EndoS in NZ131
(serotype M49). Error bars indicate standard deviation from the mean. Experiments were performed in triplicate. * indicates P < 0.05, *** indicates
P < 0.001, ns indicates no significant difference.
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In vivo mouse model
Many major GAS virulence factors have been shown to
decrease overall virulence when knocked out and stu-
died in murine infection models [13-16]. It has also
been shown that EndoS has activity on all subclasses of
murine IgG [17]. Taken together, this led us to believe
that the contribution of EndoS to GAS virulence could
be studied in vivo. However, in this murine model of
infection GAS strain 5448ΔndoS showed no significant
difference in virulence compared to wild-type 5448 (Fig-
ure 3A).
However, when we studied the less virulent GAS
strain NZ131 (serotype M49) overexpressing EndoS, it
was found that strain NZ131[pNdoS] showed increased
virulence in vivo (Figure 3B) compared to wild-type
NZ131[empty vector]. This may be a function of the
relatively high level of expression of EndoS in NZ131
[pNdoS] compared to 5448 (Figure 1A).
Discussion
A single clone of the M1T1 serotype has disseminated
globally during the last few decades to represent the
leading cause of severe, invasive GAS infections [18].
The unique virulence of the M1T1 clone has been asso-
ciated with many factors including the phage-encoded
DNAse Sda1, allowing escape from neutrophil extracel-
lular traps [13,19,20], the streptococcal inhibitor of com-
plement (SIC) protein, promoting serum and
antimicrobial peptide resistance [14,21], pro-inflamma-
tory and phagocyte resistance properties of the M1T1
protein [15,22], high level expression of the pore-form-
ing cytotoxin streptolysin O (SLO) [16], and a propen-
sity for genetic mutations in the covR/S regulatory locus
promoting hypervirulence [23,24]. There exist many
inherent limitations of modeling a secreted bacterial
virulence factor in vitro and of the mouse as a surrogate
host for GAS infection studies. However, our studies do
strongly suggest that the endogenous expression of
EndoS may be redundant or dispensable for M1T1 GAS
phagocyte resistance and pathogenicity, since targeted
mutation of the other factors described above do yield
clear attenuation of virulence phenotypes in similar in
vitro and in vivo assay systems.
Conversely, pretreatment of plasma containing antibo-
dies against GAS with recombinant EndoS reduced
opsonphagocytic killing of GAS, and heterologous over-
expression of EndoS in a less virulent M49 GAS strain
conferred increased phagocyte resistance and increased
lethality in the mouse infection model. These results
suggest that high level expression or local accumulation
of EndoS in tissues could contribute to virulence in cer-
tain GAS strain backgrounds or infection scenarios, a
subject that could merit future analysis in larger clinical
or molecular epidemiologic surveys.
EndoS is highly conserved among GAS serotypes and
can also be found in Streptococcus equi and zooepidemi-
cus [12]. Therefore, it was somewhat surprising that we
could not detect a significant contribution to GAS viru-
lence in vivo. This may be due to the limitations of the
mouse model used, and the expression levels of EndoS
during the murine infection. The expression level of this
enzyme during a human infection could have an impact










Figure 2 Opsonized bacterial survival in U937 monocytic cell
killing assays. (A) M1T1 GAS strain 5448 and isogenic ndoS
knockout, 5448ΔndoS. (B) Exogenous pretreatment of plasma with
rEndoS prior opsonization of GAS. (C) Heterologous expression of
EndoS in NZ131 (serotype M49). Error bars indicate standard
deviation from the mean. * indicates P < 0.05, ** indicates P < 0.01,
*** indicates P < 0.001, ns indicates no significant difference.
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to be investigated. The specificity of EndoS activity
towards IgG suggests that the enzyme may have an
important role in the pathogenesis of GAS, yet to be
discovered.
Finally, whether or not GAS can effectively deploy this
unique enzymatic activity targeted IgG N-glycosylation
to promote its own survival in the host (as is intuitively
appealing), the enzyme itself has already proven a pro-
mising lead biotherapeutic for treatment of antibody-
mediated inflammatory pathologies [17,25-29].
Conclusions
We conclude that in a highly virulent M1T1 back-
ground, EndoS has no significant impact on GAS phago-
cyte resistance and pathogenicity. However, our
overexpression experiments could indicate that local
accumulation or high levels of expression of EndoS can
contribute to virulence in certain GAS strains, or in
other infection scenarios than the systemic infection
model used in this study.
Methods
Bacterial strains and growth
GAS strain 5448 (serotype M1T1, ndoS-positive) and
GAS strain NZ131 (serotype M49, ndoS-negative) are
well-characterized and were selected for use in this
study [30,31]. Escherichia coli MC1061 was used as
cloning tool [32]. The streptococcal and E. coli strains
were propagated on Todd-Hewitt agar (THA). For selec-
tion, erythromycin (erm) was used at 5 μg/mL (5448), 2
μg/mL (NZ131) and 500 μg/mL (MC1061). GAS and its
isogenic mutant were grown in Todd-Hewitt broth
(THB (Difco, Detroit, MI)) at 37°C without shaking. For
in vitro and in vivo experiments, fresh overnight cultures
were diluted 1:10 in THB and grown to mid logarithmic
phase (OD600 = 0.4) and resuspended in PBS, or in mid-
log supernatants for neutrophil assays with NZ131. For
analysis of streptococcal supernatants, strains were
grown in C-medium (0.5% (w/v) Proteose Peptone no. 2
(Difco), 1.5% (w/v) yeast extract, 10 mM K2HPO4, 0.4
mM MgSO4, 17 mM NaCl pH 7.5) to maximize EndoS
expression.
GAS mutants
EndoS is encoded by the gene ndoS. A precise, in-frame
allelic replacement of ndoS with chloramphenicol trans-
ferase, cat, was created in M1T1 GAS strain 5448 by a
method previously described [13] and was denoted
5448ΔndoS. Briefly, a 798 bp fragment upstream, and
987 bp fragment downstream of ndoS was amplified








respectively. The primers adjacent to ndoS contained 30
bp overhang of the cat gene corresponding to the 5’ and
3’ ends of cat, respectively. The upstream and down-
stream fragments were combined with the 650 bp cat
gene in a fusion PCR using primers ndoS-up-F-XbaI and
ndoS-dn-R-BamHI. This triple fragment was digested
using restriction enzymes XbaI and BamHI and ligated
using T4 ligase into the temperature sensitive vector
pHY304, bearing erythromycin resistance, to generate
the knockout plasmid pHY-ndoS-KO. pHY-ndoS-KO
was transformed into GAS 5448 by electroporation and
transformants were grown at the permissive temperature
of 30°C with erythromycin. Transformants were then
grown at the non-permissive temperature of 37°C with
erythromycin present to select for homologous recombi-
nation and integration of the plasmid into the genome.
Single crossovers were confirmed by PCR analysis.
Relaxation of the plasmid was carried out at 30°C with
A BM1T1 knockout in vivo Heterologous expression
in vivo
Figure 3 Survival curves of female CD-1 mice following intraperitoneal challenge with GAS. (A) M1T1 GAS strain 5448 and isogenic ndoS
knockout, 5448ΔndoS, at 2 × 107 cfu with 5% mucin (n = 6). (B) Heterologous expression of EndoS in NZ131 (serotype M49) at 5 × 108 cfu with
5% mucin (n = 10).
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no antibiotic selection to allow the plasmid to reform,
outside the chromosome. Growing the bacteria at 37°C
without antibiotic pressure resulted in loss of the plas-
mid. Finally, screening for erythromycin sensitive colo-
nies was used to identify double crossover events and
allelic replacement mutants were confirmed by PCR. In
frame allelic replacement ndoS mutant, 5448ΔndoS, was
confirmed by multiple PCR reactions showing the inser-
tion of the cat gene and absence of the ndoS gene in
the genome. Heterologous expression of EndoS in M49
GAS strain NZ131 was established by transformation
with the EndoS expression plasmid pNdoS. ndoS was
amplified from the M1 genome using primers ndoS-F-
EcoRI (GCGAATTCATGGATAAACATTTGTTGG-
TAAAAAGAAC) and ndoS-R-BamHI (GCGGATCCT-
TATTTTTTTAGCAGCTGCCTTTTCTC), digested
with EcoRI and BamHI prior to T4-ligation into the
expression vector pDCerm, denoted pNdoS. As a con-
trol, GAS strain NZ131 was transformed with the empty
vector pDCerm to generate NZ131[empty vector].
Western blot
Supernatants from stationary phase (16 h) GAS strains
5448, 5448ΔndoS, NZ131[empty vector] and NZ131
[pNdoS] were precipitated with 5% final concentration
of trichloroacetic acid and separated on a 10% SDS-
PAGE gel and blotted onto a methanol activated PVDF
membrane. The membrane was blocked in 5% skimmed
milk (Difco) for 1 h and washed 3 × 10 minutes in
phosphate buffered saline, PBS (137 mM NaCl, 2.7 M
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). The
membrane was then incubated with polyclonal rabbit
antiserum against rEndoS at 1:2000 dilution in 0.5%
skimmed milk and incubated for 1 h at 37°C. The mem-
brane was washed as before and incubated with goat
anti-rabbit IgG conjugated with Horse radish peroxidase
(Bio-Rad), at 1:5,000 in 0.5% skimmed milk for 1 h at
37°C. After washing, the membrane was developed using
Supersignal West Pico Chemiluminescent (Thermo
Scientific, Rockford, IL) and analyzed on a Chemidoc
XRS (Bio-Rad, Hercules, CA).
Lectin blot
Supernatants from GAS strains 5448, 5448ΔndoS,
NZ131[empty vector] and NZ131[pNdoS] at stationary
phase (16 h) was incubated with 1 μg murine IgG
(mIgG) for 2 h at 37°C at static conditions. As a positive
control, IgG was incubated with 1 μg rEndoS. The gly-
can hydrolyzing activity was analyzed with SDS-PAGE
and lectin blot using biotinylated Lens culinaris aggluti-
nin (LCA) (Vector Laboratories, Burlingame, CA). LCA
lectin recognizes the a-1,3 mannose residue found on
the N-linked glycan on IgG. Briefly, the supernatants
and mIgG were separated on 10% SDS-PAGE gels,
onestained with Coomassie blue and the other blotted
onto Immobilon PVDF membranes (Millipore, Bedford,
MA). The membrane was blocked in lectin buffer (10
mM HEPES, 0.15 M NaCl, 0,1% Tween 20, 0.01 mM
MnCl2, 0.1 mM CaCl2, pH = 7.5) for 1 h. 10 μg LCA in
lectin buffer was incubated with the membrane for 1 h
at RT. The membrane was then washed for 3 × 10 min
in lectin buffer and incubated with 2 μg streptavidin
linked HRP (Vector Laboratories) for 1 h. After washing
as above the blot was developed using Supersignal West
Pico Chemiluminescent (Thermo Scientific) as described
for Western blots.
Neutrophil killing assay
Neutrophils were purified from healthy donors using
PolyMorphPrep-kit (Axis-Shield, Oslo, Norway) and
RBCs lysed with sterile H20 as previously described [33].
Neutrophils were seeded at 2 × 105 cells/well in 96-well
microtiter plates in RPMI.
Plasma was obtained from healthy volunteers as pre-
viously described [33]. All neutrophil and plasma donors
exhibited high serum titer (>1:20,000) against serotype
M1 and M49 GAS (Additional file 1 Table S1). GAS
strains were grown as described and opsonized for 1 h
at 37°C in 80% plasma, with or without pretreatment
using recombinant EndoS (rEndoS) under rotating con-
ditions. For pretreatment, 1 mL of plasma was incubated
with 50 μg of rEndoS or PBS (control) at 37°C for 2 h
with rotation. The bacteria were then diluted to the
desired concentration in RPMI with a final concentra-
tion of 2% plasma and added to the neutrophils at a
multiplicity of infection (MOI) of 10 bacteria per cell.
Control wells contained GAS in RPMI and 2% plasma
without neutrophils. The plate was centrifuged at 500 ×
g for 10 min and incubated for 30 min at 37°C with 5%
CO2 before being serially diluted in sterile H2O and tri-
plicate wells were plated on Todd-Hewitt agar (THA)
plates for enumeration. Percent survival of the bacteria
was calculated relative to control wells. Data from three
separate experiments were normalized to 5448 or
NZ131[empty vector] and combined.
Monocyte killing assay
The human monocytic cell line U937 was seeded at 5 ×
105 cells/well in RPMI supplemented with 10% fetal
bovine serum (FBS) in 24-well plates. GAS was grown
and pre-opsonized in human plasma with or without
rEndoS treatment, as described above. Bacteria were
grown as described above and added to the U937 cells
at MOI = 10 and incubated at 37°C with 5% CO2. Sam-
ples were collected at 1, 2, 3 and 4 h when monocytes
were lysed with 0.025% Triton X-100 (MP Biomedicals,
Aurora, OH) and triturated vigorously. Surviving bac-
teria from triplicate wells were plated on THA for
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enumeration. Percentage of surviving bacteria was calcu-
lated relative to the initial innoculum. Data from at least
three separate experiments were normalized to 5448 or
NZ131[empty vector] and combined.
Determination of donor serum titers
Blood from healthy human donors was collected in glass
venous blood collection tubes with no additives (BD
Biosciences, San Jose, CA) and clotted at room tempera-
ture for 15 min. Blood was centrifuged at 3,200 × g for
10 min at 4°C. The serum fraction was collected and
stored at -80°C.
GAS strains NZ131 (serotype M49) and 5448 (sero-
type M1) were grown to mid-log phase in THB. Bacteria
were resuspended in PBS and heat-killed at 95°C for 10
min. Heat-killed bacteria were mixed with a final con-
centration of 0.1 M NaHCO3 pH 9.6 and 106 bacteria
per well were coated to 96-well high-bind ELISA plates
(Costar, Cambridge, MA) at 4°C overnight. Plates were
washed with PBS + 0.05% Tween (PBS-T) and blocked
with 4% BSA + 10% FBS in PBS-T for 1 h at 37°C.
Serum samples were diluted in blocking solution and
incubated for 2 h at 37°C. Plates were washed with PBS-
T and incubated with 1:5000 dilution of HRP-conju-
gated goat anti-human IgG antibody (Promega, Madi-
son, WI) for 1 h at room temperature. Plates were
washed five times with PBS-T and incubated with TMB
substrate reagent (BD OptEIA TMB Substrate Reagent
Set, BD Biosciences) at room temperature for 30 min.
The reaction was stopped with an equal volume of 0.2
N sulfuric acid, and the plate was read at 450 nm. End
point titer was determined as the dilution giving signal
above a calculation cutoff determined using a mouse
serum negative control and the calculation method
described in [34].
In vivo mouse model
To evaluate the contribution of EndoS to GAS virulence
in vivo, we utilized a murine model of systemic infec-
tion. GAS strains were grown as described and resus-
pended in PBS with 5% mucin for an inoculum of 2 ×
107 cfu for WT M1T1 strain 5448 and isogenic mutant
5448ΔndoS, and 5 × 108 cfu for NZ131[empty vector]
and NZ131[pNdoS]. 8-10 week old female CD-1 mice (n
= 6 for 5448, n = 10 for NZ131) were infected intraperi-
toneally with GAS strains and mortality was monitored
daily for 10 days.
Statistical analysis
Cfu enumeration in neutrophil and monocyte killing
assays were statistically analyzed by unpaired Student’s
t-test. Differences were considered significant if P <0.05.
The in vivo results were evaluated with log-rank (Man-
tel-Cox) test for comparison of survival curves.
Differences in survival were considered significant if P <
0.05. All statistical analysis was performed using Graph-
Pad Prism v.5 (GraphPad Software).
Ethical approval
Permission to collect human blood under informed con-
sent was approved by the UCSD Human Research Pro-
tections Program. All animal use and procedures were
approved by the UCSD Institutional Animal Care and
Use Committee.
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